Huadong Medicine

DGAP-News: Heidelberg Pharma Reports Outcome of the Annual General Meeting 2022

Retrieved on: 
화요일, 6월 28, 2022
BCMA, PSMA, CEO, HPHA, Frankfurt Stock Exchange, FSE, Annual, Company, Non-Hodgkin lymphoma, ISIN, CFO, West Coast of Vancouver Island Aquatic Management Board, Supervisory board, Annual general meeting, Multiple myeloma, CD37, Generic drug, Pharmaceutical industry, Fine chemical, EU, Huadong Medicine

Ladenburg, Germany, 28 June 2022 Heidelberg Pharma AG (FSE: HPHA) announced that the shareholders of the Company approved the resolutions of the administration with large majorities (ranged from 98.49% to 99.99%) during the virtual Annual General Meeting today:

Key Points: 
  • Ladenburg, Germany, 28 June 2022 Heidelberg Pharma AG (FSE: HPHA) announced that the shareholders of the Company approved the resolutions of the administration with large majorities (ranged from 98.49% to 99.99%) during the virtual Annual General Meeting today:
    Presence (including postal voting) at the Annual General Meeting 2022 corresponded to 82.26% of the current share capital.
  • On behalf of the Management Board, I would like to thank the shareholders of Heidelberg Pharma AG for their confidence in our Company and their long-standing support.
  • Please find more information about the Annual General Meeting including the voting results here: https://heidelberg-pharma.com/en/AGM .
  • Heidelberg Pharma AG is based in Ladenburg, Germany, and is listed on the Frankfurt Stock Exchange: ISIN DE000A11QVV0 / WKN A11QVV / Symbol HPHA.

Sinclair Pharma Announces New Board Appointment and Senior Management Change

Retrieved on: 
목요일, 5월 19, 2022
EBD, CGE, Chinese Pharmaceutical Association, Leadership, Health, HMC, Culture, EDB, Industry, Pharma, Safety, Foundation, Group, Acquisition, CFO, Huadong Medicine, Growth, CEO, Television set, Management, EU

LONDON, May 19, 2022 /PRNewswire-PRWeb/ -- Sinclair Pharma ("Sinclair", http://www.sinclairpharma.com) a global aesthetics company headquartered in London and fully-owned subsidiary of Huadong Medicine Company Limited announces that Chris Spooner is stepping down as CEO to be replaced by Miguel Pardos, who will also join the board of Sinclair. Alan Olby, former CFO will also be leaving the company.

Key Points: 
  • Sinclair Pharma ("Sinclair", http://www.sinclair.com ) a global aesthetics company headquartered in London and fully-owned subsidiary of Huadong Medicine Company Limited announces that Chris Spooner is stepping down as CEO to be replaced by Miguel Pardos, who will also join the board of Sinclair.
  • LONDON, May 19, 2022 /PRNewswire-PRWeb/ -- Sinclair Pharma ("Sinclair", http://www.sinclairpharma.com ) a global aesthetics company headquartered in London and fully-owned subsidiary of Huadong Medicine Company Limited announces that Chris Spooner is stepping down as CEO to be replaced by Miguel Pardos, who will also join the board of Sinclair.
  • Mr Spooner presided over the transformation of Sinclair from a small and unprofitable medicinal dermatology company to a major player in the aesthetic market.
  • Miguel Pardos, CEO of Sinclair commented, "I feel privileged to be taking the helm at Sinclair.

ImmunoGen Reports Recent Progress and First Quarter 2022 Financial Results

Retrieved on: 
금요일, 5월 6, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, COVID-19, ASCO, American Society of Clinical Oncology, U.S. Securities and Exchange Commission, Society, Gynecologic Oncology (journal), Bevacizumab, PFS, Eli Lilly and Company, File, AML, IND, ImmunoGen, Venetoclax, Maintenance, Azacitidine, Carboplatin, Control, Food, Safety, Society of Gynecologic Oncology, Research, Patient, BLA, Security (finance), Acute myeloid leukemia, Program, ASH, FDA, Cancer, US Foods, Huadong Medicine, IMGN, György Enyedi (geographer), SGO, Capital expenditure, CMC, ID, PDUFA, Annual general meeting, Awareness, Priority review, Vaccine, Pharmaceutical industry, Medical imaging, Platinum, Risk management, Video game, Online gambling, Company, Lilly, BPDCN

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today reviewed recent progress in the business and reported financial results for the quarter ended March 31, 2022.

Key Points: 
  • ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today reviewed recent progress in the business and reported financial results for the quarter ended March 31, 2022.
  • Total revenues were $38.1 million for the quarter ended March 31, 2022 compared to $15.7 million for the quarter ended March 31, 2021.
  • Operating expenses for the quarter ended March 31, 2022 were $60.9 million, compared with $44.6 million for the same quarter in 2021.
  • ImmunoGen had $437.7 million in cash and cash equivalents as of March 31, 2022, compared with $478.8 million as of December 31, 2021.

Ashvattha Therapeutics Announces $69 Million in Series B Financing and up to $45M Exclusive License Agreement with Huadong to Advance Hydroxyl Dendrimer-Based Precision Medicines

Retrieved on: 
수요일, 4월 27, 2022
DME, HDT, ALS, Immunity, CEO, Neurology, Multiple organ dysfunction syndrome, Infection, HD, COVID-19, Therapeutic index, Endocrinology, Research, NAC, Natural capital, Traffic barrier, Microglia, Medicine, Inflammation, Therapy, AMD, VEGFR, GLOBE, Patient, Neoplasm, Amyotrophic lateral sclerosis, Trial of the century, Technology, Ashvattha, Ecosystem, Diabetic retinopathy, Neurodegeneration, HDS, Venture round, Neuro, Partnership, Disease, Precision medicine, Johns Hopkins University, Interim, Transfusion-related acute lung injury, Security (finance), Pharmaceutical industry, Vaccine, Ophthalmology, Huadong Medicine

REDWOOD CITY, Calif., April 27, 2022 (GLOBE NEWSWIRE) -- Ashvattha Therapeutics (“Ashvattha”), a clinical stage company developing novel hydroxyl dendrimer therapeutics, today announced it has secured $69 million in a Series B financing and in a separate agreement entered an exclusive licensing deal with Huadong Medicine. Proceeds will support the advancement of Ashvattha’s pipeline of hydroxyl dendrimer therapeutics (HDTs), including multiple clinical stage programs. Ashvattha launched a Phase 2 study in severe COVID-19 earlier this year and in 2022 plans to launch a Phase 2 study in wet AMD/DME and Phase 1/2 study in ALS.

Key Points: 
  • Proceeds will support the advancement of Ashvatthas pipeline of hydroxyl dendrimer therapeutics (HDTs), including multiple clinical stage programs.
  • The exclusive licensing agreement with Huadong which includes up to $45 million advanced payments for product development, grants Huadong development and commercialization rights to its pipeline assets in China and parts of southeast Asia.
  • Mr. Lv Liang, Chairman of Huadong Medicine, added, We believe Ashvatthas hydroxyl dendrimer platform has the potential to produce highly selective drugs.
  • Ashvattha Therapeutics is a clinical-stage biotech company developing novel hydroxyl dendrimer therapeutics (HDTs) targeting unmet medical needs in ophthalmology, neurology, inflammation and neuro-oncology.

DGAP-News: Heidelberg Pharma announces financial figures for fiscal year 2021 and provides business update

Retrieved on: 
금요일, 4월 1, 2022
AML, Gesellschaft mit beschränkter Haftung, Spanish mythology, Research, Winship Cancer Institute, American Association for Cancer Research, HPHA, Depreciation, ATACS, Annual report, FSE, Kidney, USD, Marketing, Redhill, ADC, Magenta, Conference, Science Translational Medicine, American Association, EDT, Myelodysplastic syndrome, CD117, Histology, University Hospital Heidelberg, Annual general meeting, Tax, Income, MD Anderson Cancer Center, Phase, IFRS, IFRS 15, Patent, Huadong Medicine, Clinical trial, AACR, Indiana University School of Medicine, Conference call, Government, Amanitin, Multiple myeloma, EBIT, Patient, Partnership, Company, Emory University, Group, Safety, COVID-19, Transplant, R, Security (finance), Fine chemical, Pharmaceutical industry, Renewable energy, Film, Medicine, ATAC, EUR

The Heidelberg Pharma Group includes two entities, Heidelberg Pharma AG and Heidelberg Pharma Research GmbH.

Key Points: 
  • The Heidelberg Pharma Group includes two entities, Heidelberg Pharma AG and Heidelberg Pharma Research GmbH.
  • The Heidelberg Pharma Group recognized comprehensive income and a net loss of EUR -26.1 million (previous year: EUR -18.4 million) in the 2021 fiscal year.
  • These will primarily comprise the sales revenue generated by Heidelberg Pharma Research GmbH and, to a lesser extent, potential milestone payments to Heidelberg Pharma AG.
  • Financing requirements in the 2022 fiscal year for Heidelberg Pharma AG's business operations are expected to increase compared to 2021.

DGAP-News: Heidelberg Pharma and Huadong Announce Strategic Partnership, Including Equity Investment

Retrieved on: 
토요일, 3월 5, 2022
People, ISIN, B-cell lymphoma, Multiple myeloma, ODI, Knowledge, Board, HPHA, SZ, Acquisition, Nephrology, Partnership, ATAC, Prospectus, Federal Financial Supervisory Authority, FSE, Pharma, CFO, Republic, Stock, Medicine, Company, CEO, Gesellschaft mit beschränkter Haftung, CET, Frankfurt Stock Exchange, Q&A, Conference call, Spanish mythology, Partner (business rank), Supervisory board, BCMA, Ecosystem, Science, USD, ADC, CD37, Marketing, Exercise, Patient, Research, EUR, Cancer, PSMA, Conference, Diabetes, Fine chemical, Security (finance), Generic drug, Huadong Medicine, Heidelberg Pharma, Huadong Medicine, HEIDELBERG PHARMA, HUADONG MEDICINE

Heidelberg Pharma and Huadong Announce Strategic Partnership, Including Equity Investment

Key Points: 
  • Heidelberg Pharma and Huadong Announce Strategic Partnership, Including Equity Investment
    The issuer is solely responsible for the content of this announcement.
  • Dr. Jan Schmidt-Brand, CEO and CFO of Heidelberg Pharma, commented: "We are excited to enter this major partnership with Huadong.
  • Mr. Liang Lu, Chairman of the Board and CEO of Huadong Medicine, added: "Heidelberg Pharma is an emerging leader in the ADC space.
  • We are also committed to supporting Heidelberg Pharma to become a world ADC leader, by the substantial equity investment and access to Huadong's ADC ecosystem."

ImmunoGen Reports Recent Progress and 2021 Financial Results

Retrieved on: 
금요일, 2월 25, 2022
Oncology, Health, Clinical Trials, General Health, Pharmaceutical, Biotechnology, Head, Security (finance), ID, COVID-19, FACP, CMC, IND, Society of Gynecologic Oncology, Chemistry, Capital expenditure, Research, Society, Board, SGO, Medical Affairs Bureau, Azacitidine, AML, ImmunoGen, Initiate, Sale, Jazz Pharmaceuticals, Gynecologic Oncology (journal), U.S. Securities and Exchange Commission, Medicine, BLA, Food, György Enyedi (geographer), Leadership, Maintenance, Director, Ovarian cancer, Population, MPH, Bevacizumab, Eli Lilly and Company, US Foods, IMGN, Patient, Carboplatin, Control, Clinical trial, ASH, Venetoclax, FDA, Lilly, Cancer, Vaccine, Management, Pharmaceutical industry, Platinum, Risk management, Online gambling, Airline, Company, BPDCN, Huadong Medicine, MD

ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today reviewed recent progress in the business and reported financial results for the quarter and year ended December 31, 2021.

Key Points: 
  • ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today reviewed recent progress in the business and reported financial results for the quarter and year ended December 31, 2021.
  • Together with the appointment of key leadership positions and an oversubscribed follow-on offering in the fourth quarter, this progress positions us for success in 2022 and beyond.
  • Initiated accrual in PICCOLO, a single-arm study of mirvetuximab monotherapy in FR-high recurrent platinum-sensitive ovarian cancer.
  • ImmunoGen expects that its current cash, combined with anticipated product and collaboration revenues, will fund operations into 2024.

AKSO and Huadong Medicine Announce Strategic Collaboration to Develop and Commercialize AB002 in Asia Pacific Ex-Japan

Retrieved on: 
수요일, 2월 9, 2022
Biotechnology, Infectious Diseases, Health, Pharmaceutical, Oncology, Tumor microenvironment, Genetic disorder, DEEP, Nephrology, Autoimmune disease, NK, PD-1, Cancer, Marketing, IND, PD-L1, Patient, Population, Science, Therapy, PD-L2, Medicine, Drug development, Diabetes, Half-life, Degenerative disease, Partner, Cell, Fine chemical, Pharmaceutical industry, Huadong Medicine

AB002 is a first-in-class molecule that leverages AKSOs proprietary DEEP platform to neutralize PD-L2 and PD-L1, while activating NK cells via an IL-15 agonist.

Key Points: 
  • AB002 is a first-in-class molecule that leverages AKSOs proprietary DEEP platform to neutralize PD-L2 and PD-L1, while activating NK cells via an IL-15 agonist.
  • We are excited to partner with Huadong Medicine to accelerate AB002s development and deliver this innovative therapeutic to patients with unmet urgent needs.
  • Leveraging Huadong Medicines R&D capabilities, we will work closely with AKSO Biopharmaceutical to accelerate the development of AB002 to benefit the cancer patients all over the world.
  • Huadong Medicine will be responsible for clinical development, regulatory submissions and commercialization of AB002 in the region and jointly steer IND-enabling tasks with AKSO via the Joint Research Committee.

Global Facial Injectables Market (2021 to 2026) - Industry Trends, Share, Size, Growth, Opportunity and Forecasts - ResearchAndMarkets.com

Retrieved on: 
월요일, 9월 27, 2021
Science, Other Science, Biotechnology, Practice Management, Pharmaceutical, Surgery, Health, Other Health, Elasticity, Collagen, Traction, Social media, Face, Huadong Medicine, Pharma, Hyaluronic acid, Skin, COVID-19, Cosmetics

facial injectables are administered on specific areas of the face to enhance the physical appearance of the skin.

Key Points: 
  • facial injectables are administered on specific areas of the face to enhance the physical appearance of the skin.
  • These injectables are generally made using collagen, hyaluronic acid and calcium hydroxylapatite that help restore the elasticity of the skin.
  • Currently, facial injectables are gaining traction worldwide as they are safe, cost-effective and require minimal downtime.
  • Moreover, as excessive sun exposure leads to tissue breakdown of the skin, the demand for facial injectables is escalating among outgoing individuals.

Huadong Medicine and Insilico Medicine enter co-development partnership to advance oncology drug discovery by hitting undruggable targets

Retrieved on: 
수요일, 9월 8, 2021

SHANGHAI, Sept. 8, 2021 /PRNewswire/ --Huadong Medicine (SZ.000963) and Insilico Medicine ("Insilico"), an end-to-end artificial intelligence (AI)-driven drug discovery company, announced today that the companies have entered into a co-development partnership to accelerate the discovery of breakthrough small-molecule therapeutics by leveraging an innovative approach to oncology.

Key Points: 
  • SHANGHAI, Sept. 8, 2021 /PRNewswire/ --Huadong Medicine (SZ.000963) and Insilico Medicine ("Insilico"), an end-to-end artificial intelligence (AI)-driven drug discovery company, announced today that the companies have entered into a co-development partnership to accelerate the discovery of breakthrough small-molecule therapeutics by leveraging an innovative approach to oncology.
  • Pursuant to the collaboration agreement, Insilico and Huadong Medicine will launch a new drug discovery project involving the research and development (R&D) teams of both parties.
  • The project team will interfere with protein-protein interactions to hit undruggable targets that regulate tumor growth.
  • In addition, Huadong Medicine's R&D organization currently has more than 1000 FTEs involved in drug discovery, preclinical research, clinical research, CMC, and RA.